Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures

Stock Information for Zynerba Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zynerba Pharmaceuticals Inc.

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SOVO, DBTX, DM, ZYNE
Moore Kuehn Encourages SOVO, DBTX, DM and ZYNE Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPRI, CEQP, CELL, ZYNE

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.